Skip to main content
. 2020 May 15;1(3):100052. doi: 10.1016/j.jtocrr.2020.100052

Figure 4.

Figure 4

Progression-free survival on first-line chemotherapy (A) according to KRAS mutations and (B) according to KRAS transition versus transversion mutation.